GSK Cervarix Setback: FDA Questions On HPV Vaccine Bode Well For Merck
Executive Summary
The launch of GlaxoSmithKline human papilloma virus vaccine Cervarix will be further delayed behind Merck's competing Gardasil vaccine after FDA issued a "complete response" letter related to the BLA Dec. 17
You may also be interested in...
Novartis Hopes To Avoid Long FDA Delay For MF59 Adjuvant in Flu Vaccine
Novartis is trying to convince FDA that its squalene vaccine adjuvant MF59 is a non-threatening vaccine component that does not deserve to get caught in a long regulatory review of new vaccine technologies
Novartis Hopes To Avoid Long FDA Delay For MF59 Adjuvant in Flu Vaccine
Novartis is trying to convince FDA that its squalene vaccine adjuvant MF59 is a non-threatening vaccine component that does not deserve to get caught in a long regulatory review of new vaccine technologies
GSK Will Answer FDA “Complete Response” Letter For Cervarix In Q2
GlaxoSmithKline will answer FDA's "complete response" letter for its Cervarix BLA in the second quarter, but the firm expects the product will require advisory committee review for final approval, CEO JP Garnier said during GSK's year-end earnings call